Amgen’s migraine drug Aimovig continues to impress with its efficacy in late-stage studies. Source: BioSpace

The company expects the new facility will include commercial manufacturing capabilities in 18 to 24 months. Source: BioSpace

The companies will collaborate on research to study a previously unrecognized role for peripheral immune cells in the pathology of central nervous system disorders. Source: BioSpace

The year is already off to a good start with mergers and acquisitions in the biopharma industry. Source: BioSpace

Fortis Therapeutics is focused on immuno-oncology, specifically on developing an ADC for multiple myeloma and late-stage prostate cancer, including both the adenocarcinoma and neuroendocrine types. Source: BioSpace

The announcement sent shares of Juno soaring more than 27 percent in pre-market trading to $86.26. Source: BioSpace

Marshall co-founded more than a decade ago, and which was acquired by Sosei in 2015. Source: BioSpace

The deal has Sanofi paying $105 per share in cash. Source: BioSpace

Acorn Pacific Ventures led the round, with participation from GP Capital and all existing major investors. Source: BioSpace

Indalo Therapeutics is based in St. Louis and was formed in October 2016 from the merger of Antegrin Therapeutics and Cascadia Therapeutics. Source: BioSpace